National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00063193|
Recruitment Status : Completed
First Posted : June 25, 2003
Last Update Posted : January 20, 2016
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease||Drug: minocycline Drug: creatine||Phase 2|
Parkinson's disease (PD) affects nearly a million Americans, a number that will increase over the coming decades as the population ages. While available medical therapies are usually effective for controlling symptoms in the initial years following diagnosis, higher doses of multiple agents are required over time, with increasing side effects and incomplete control of symptoms. Although these treatments can dramatically improve the lives of patients with PD initially, they do not address the underlying causes of the disease or the inevitable disease progression.
This multi-center, randomized, double-blind trial will involve 42 trial centers in the United States and Canada, and enroll 195 people with PD. The primary objective of this neuroprotection trial is to identify agents capable of slowing the progression of PD. In the trial, investigators will assess the impact of minocycline and creatine on the progression of PD and determine if it is futile or non-futile to proceed with further study of these agents.
In this study, subjects with early, untreated PD will be equally randomized into one of the three study arms: 1.) the group that receives active minocycline and placebo instead of creatine, 2.) the group that receives active creatine and placebo instead of minocycline, or 3.) the group that receives placebo instead of minocycline and creatine. Subjects will remain on the blinded study drug for 18 months.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||195 participants|
|Official Title:||A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease|
|Study Start Date :||May 2003|
|Actual Primary Completion Date :||May 2005|
|Actual Study Completion Date :||July 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00063193
|United States, New York|
|University of Rochester Medical Center|
|Rochester, New York, United States, 14620|
|Principal Investigator:||Karl Kieburtz, M.D., M.P.H.||University of Rochester|
|Principal Investigator:||Barbara Tilley, Ph.D.||Medical University of South Carolina|